BioAge Labs (BIOA) Stock News, Jun-Nov 2025

BioAge Labs (NASDAQ:BIOA) has initiated a Phase 1 clinical study of BGE-102, a novel brain-penetrant NLRP3 inhibitor developed in collaboration with HitGen (SSE:688222). The drug candidate, discovered using HitGen's DNA-encoded library (DEL) technology platform, is being developed initially for obesity treatment.

BGE-102 is an orally available small molecule that targets NLRP3, a key driver of age-related inflammation implicated in neurodegenerative conditions, cardiovascular disease, and metabolic disorders. The clinical trial initiation triggers an undisclosed milestone payment to HitGen under their collaboration agreement.

The partnership, which began with successful hit identification in April 2021, has resulted in joint patent filings and a published research paper in February 2024. Both companies continue to collaborate on additional drug discovery programs using HitGen's DEL platform, which contains over 1.2 trillion small molecules.

BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, plan to sell a minor portion of their shareholdings in the company. The company disclosed this information in compliance with EU Market Abuse Regulation requirements.

BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its partner Eisai received FDA approval for LEQEMBI IQKLIK™, a subcutaneous autoinjector version of lecanemab for maintenance treatment of early Alzheimer's disease. The new formulation will launch on October 6, 2025.

After 18 months of initial Leqembi intravenous treatment, patients can either continue with IV infusions every four weeks or switch to the new weekly 360 mg subcutaneous injection. Leqembi uniquely targets both amyloid plaque and protofibrils, potentially impacting tau accumulation. The treatment aims to slow disease progression and maintain therapeutic benefits through continuous maintenance therapy.

BioAge Labs (NASDAQ: BIOA), a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major investor conferences in September 2025.

The company will present at Citi's 2025 Biopharma Back to School Conference in Boston (September 2-3) and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York (September 8-10). CEO Kristen Fortney and CFO Dov Goldstein will conduct fireside chats and one-on-one meetings at both events. Webcasts will be available live and archived for 30 days on the company's investor relations website.

BioAge Labs (NASDAQ:BIOA) has initiated Phase 1 clinical trials for BGE-102, a novel brain-penetrant NLRP3 inhibitor targeting obesity. The compound represents a new class of NLRP3 inhibitors with high potency and once-daily oral dosing potential.

In preclinical studies, BGE-102 demonstrated impressive results, achieving up to 15% weight loss as monotherapy and 25% weight reduction when combined with semaglutide. The Phase 1 trial will evaluate safety, tolerability, and pharmacological properties in healthy participants through a randomized, double-blind, placebo-controlled study.

BioAge expects initial SAD data by end of 2025 and plans to advance to a proof-of-concept obesity study in 2026, with top-line data expected by end of 2026.

BioAge Labs (NYSE:BIOA) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical pipeline and discovery platform. The company completed IND-enabling studies for BGE-102, their oral NLRP3 inhibitor for obesity treatment, with Phase 1 trials set to begin in 2H 2025. BioAge expanded its APJ agonist pipeline through a partnership with JiKang Therapeutics and filed patents for novel oral small molecules.

Financial results showed R&D expenses of $19.8M (up from $10.5M in Q2 2024) and a net loss of $21.6M. The company maintains a strong financial position with $313.4M in cash and equivalents, expected to fund operations through 2029.

BioAge Labs (NASDAQ: BIOA) announced new preclinical data presentation at ADA's 85th Scientific Sessions regarding their APJ agonist treatment for diabetic obesity and heart failure. The data shows that APJ activation, combined with incretin therapy, demonstrated significant benefits in preclinical models. Key findings include improved glycemic control with a 25% enhancement in glucose tolerance and reduced HbA1c levels in diabetic obesity models. In heart failure models, the treatment showed cardioprotective effects and reduced cardiac hypertrophy. The company is developing both oral and injectable APJ agonist formulations, targeting an IND filing for 2026. The research suggests APJ agonists could act as exercise mimetics, potentially doubling the weight loss effects of GLP-1 receptor agonists while improving body composition and muscle function.

BioAge Labs (NASDAQ: BIOA) has announced a major expansion of its drug discovery platform through a collaboration with Norwegian diagnostics company Age Labs AS to analyze samples from the HUNT Biobank. The company will profile over 17,000 samples from 6,000+ participants, generating millions of molecular measurements to enhance their proprietary human aging data platform. The analysis will focus on participants who developed cardiometabolic disease (>50%) and cognitive decline/dementia (>35%), using Standard BioTools' SomaScan assay to quantify thousands of proteins per sample. This initiative will complement BioAge's existing platform that contains over 50 million molecular measurements collected across five decades, with exclusive drug discovery rights to the partnership-generated data.

BioAge Labs has expanded its APJ agonist pipeline through two significant developments. First, the company entered an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody that is 10-fold more potent than natural apelin. Second, BioAge filed a patent for new orally active small molecule APJ agonists with picomolar potency. The company's preclinical studies show that APJ agonism can double the weight loss effects of GLP-1 receptor agonists while improving muscle function and body composition. BioAge plans to advance both oral and subcutaneous APJ agonists for obesity treatment, targeting an IND filing in 2026. The JiKang agreement includes upfront payments, research funding, and potential milestone payments, while BioAge's internal small molecule program leverages computational modeling and AI design for drug development.